Skip to main content

Table 1 Baseline characteristics of heart transplant recipients included in the study

From: Ventricular assist devices as bridge to heart transplantation: impact on post-transplant infections

 

No VAD (n = 84)

VAD (n = 35)

Follow-up, years; mean (SD)

1.38 (1.07)

1.31 (1.06)

Recipient age, years; mean (SD)

47.9 (16.9)

45.7 (16.7)

Recipient gender, male; n (%)

62 (73.8)

28 (80)

Donor age, years; mean (SD)

41.3 (16.5)

40.7 (15.0)

Donor gender, male; n (%)

48 (57.1)

24 (68.6)

Prior diabetes; n (%)

15 (17.9)

4 (11.4)

BMI, kg/m2; mean (SD)

24.4 (4.7)

25.2 (4.8)

Serum creatinine, umol/l; mean (SD)

125.9 (66.0)

103.3 (47.1)

Underlying disease; n (%)

  

 - Cardiomyopathy

 - Ischemic

 - Congenital heart disease

 - Other

41 (48.8)

23 (27.4)

5 (5.9)

15 (17.9)

18 (51.4)

12 (34.3)

1 (2.9)

4 (11.4)

Cold ischemia, min; mean (SD)

151 (54.3)

164 (54.4)

Bypass time, min; mean (SD)

168 (65.6)

186 (71.1)

Induction therapy; n (%)

  

 - Basiliximab

 - ATG

 - None

7 (8.3)

71 (84.5)

6 (7.1)

6 (17.1)

24 (68.6)

5 (14.3)

Maintenance at discharge; n (%)

  

 - Tacrolimus

 - Cyclosporin

 - MMF/MPA

 - Azathioprine

 - Everolimus

 - Steroids

28 (33.3)

39 (46.4)

63 (75.0)

21 (25.0)

9 (10.7)

74 (88.1)

10 (28.6)

13 (37.1)

22 (62.9)

7 (20.0)

3 (8.6)

27 (77.1)

  1. There were no significant differences between the two groups. VAD ventricular-assist device, BMI body mass index, ATG anti-thymocyte globulin, MMF mycophenolate mofetil, MPA mycophenolic acid